1st human trial to test LBL-034 for hard-to-treat myeloma in US, China
Nanjing Leads Biolabs is planning to launch a first-in-human clinical trial to test LBL-034, an antibody-based therapy designed to trigger the immune system to…
News
Myeloma cells in lab, mice killed with nanoparticle-delivered RNA
Researchers at Tel Aviv University in Israel have developed a new nanoparticle system that can deliver RNA-based therapies designed to kill myeloma cells in…
2 Janssen therapies for RRMM earn positive opinion from EU committee
A European Medicines Agency committee has recommended that one antibody-based cancer therapy from Janssen Pharmaceuticals be approved for the treatment of relapsed and refractory…
Next IMF Patient and Family Seminar slated for Aug. 18-19 in LA
The International Myeloma Foundation (IMF) will host its second in-person Patient and Family Seminar of the year on Aug. 18-19 in Los Angeles.
Study shows less hospital time for outpatient stem cell transplants
Multiple myeloma patients undergoing a stem cell transplant in an outpatient setting spent about a week less in the hospital than those undergoing the…
FDA puts CART-ddBCMA Phase 2 trial on hold after patient’s death
The U.S. Food and Drug Administration (FDA) has placed a hold on clinical testing of CART-ddBCMA, a cell therapy that Arcellx and Kite…
Phase 1b trial of STAR-LLD combo for myeloma approved by FDA
The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 1b trial to test STAR-LLD, Starton Therapeutics’ experimental continuous delivery…
FDA asked to extend Carvykti to myeloma patients after first relapse
Janssen is asking the U.S. Food and Drug Administration (FDA) to expand approval its cell therapy Carvykti (ciltacabtagene autoleucel) to allow for earlier…
Carvykti outperforms standard care as earlier line of therapy: Analysis
Carvykti (ciltacabtagene autoleucel) significantly reduces the risk of disease progression or death in adults with multiple myeloma who received one to three prior lines…
Gene therapy targeting T-cells shows promise in myeloma animal models
A gene therapy designed by Kelonia Therapeutics to work as an off-the-shelf or readily available CAR T-cell therapy for multiple myeloma showed early…
